Product Description
Alogliptin is used along with diet and exercise to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Alogliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin in the body to control blood sugar. Alogliptin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). (Sourced from: https://medlineplus.gov/druginfo/meds/a613026.html)
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Netherlands | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Korea
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07093476 |
CT-L02-301 | P3 |
Recruiting |
Type 2 Diabetes |
2026-12-01 |
13% |
2025-08-13 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/07/2023 |
News Article |
Fuel Pump Module Assembly Market (2023 to 2029) Growing Applications Across Industry Verticals by leading players Bosch, TI Fluid Systems, Delphi |
|
03/01/2023 |
News Article |
Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers |
|
06/27/2022 |
News Article |
Cidara Therapeutics to Host Research and Development Day |
|
03/30/2022 |
News Article |
Antidiabetics Market Size Estimated to Reach $136 Billion by 2027 |